An orally active allosteric GLP-1 receptor agonist is neuroprotective in cellular and rodent models of stroke

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Zhang, Huinan ^a   Liu, Yunhan ^a   Guan, Shaoyu ^a   Qu, Di ^a   Wang, Ling ^a   Wang, Xinshang ^a   Li, Xubo ^a   Zhou, Shimeng ^a   Zhou, Ying ^a   Wang, Ning ^a   Meng, Jingru ^a   Ma, Xue ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INSULIN; LACTATE DEHYDROGENASE; PROTEIN BAX; PROTEIN BCL 2; QUINOXALINE 6,7 DICHLORO 2 METHYLSULFONYL 3 N TERT BUTYLAMINOQUINOXALINE; UNCLASSIFIED DRUG; 3-(TERT-BUTYLAMINO)-6,7-DICHLORO-2-(METHYLSULFONYL)QUINOXALINE; GLP1R PROTEIN, MOUSE; GLUCOSE BLOOD LEVEL; NEUROPROTECTIVE AGENT; PEPTIDE; QUINOXALINE DERIVATIVE; SULFONE; VENOM;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN INFARCTION SIZE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; EC50; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; MALE; MOUSE; NEUROPROTECTION; NEWBORN; NONHUMAN; SIGNAL TRANSDUCTION; TRANSIENT ISCHEMIC ATTACK; AGONISTS; ALLOSTERISM; ANIMAL; BLOOD; BRAIN; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; IC50; INFARCTION, MIDDLE CEREBRAL ARTERY; NERVE CELL; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHYSIOLOGY; PRECLINICAL STUDY; PRIMARY CELL CULTURE; REPERFUSION INJURY; VASCULARIZATION;

ADMINISTRATION, ORAL; ALLOSTERIC REGULATION; ANIMALS; APOPTOSIS; BLOOD GLUCOSE; BRAIN; CELL SURVIVAL; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; INFARCTION, MIDDLE CEREBRAL ARTERY; INHIBITORY CONCENTRATION 50; INSULIN; MALE; MICE, INBRED C57BL; NEURONS; NEUROPROTECTIVE AGENTS; PEPTIDES; PRIMARY CELL CULTURE; QUINOXALINES; REPERFUSION INJURY; SULFONES; VENOMS;

EID: 84959418961     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0148827     Document Type: Article

References (44)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Executive summary: heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation. 2014; 129(3):399-410. doi: 10.1161/01.cir.0000442015.53336.12 PMID: 24446411.
2. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999; 20(6):876-913. doi: 10.1210/ edrv.20.6.0385 PMID: 10605628.
3. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proceedings of the National Academy of Sciences of the United States of America. 1992; 89(18):8641-5. PMID: 1326760; PubMed Central PMCID: PMC49976.
4. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106 (4):1285-90. doi: 10.1073/pnas.0806720106 PMID: 19164583; PubMed Central PMCID: PMC2633544.
5. Teramoto S, Miyamoto N, Yatomi K, Tanaka Y, Oishi H, Arai H, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism. 2011; 31(8):1696-705. doi: 10.1038/jcbfm.2011.51 PMID: 21487412; PubMed Central PMCID: PMC3170947.
6. Darsalia V, Larsson M, Nathanson D, Klein T, Nystrom T, Patrone C. Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism. 2015; 35(5):718-23. doi: 10.1038/jcbfm.2015.17 PMID: 25669907; PubMed Central PMCID: PMC4420864.
7. Holscher C. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS drugs. 2012; 26 (10):871-82. doi: 10.2165/11635890-000000000-00000 PMID: 22938097.
8. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995; 44(9):1126-31. PMID: 7657039.
9. Manandhar B, Ahn JM. Glucagon-like Peptide-1 (GLP-1) Analogs: Recent Advances, New Possibilities, and Therapeutic Implications. Journal of medicinal chemistry. 2014. doi: 10.1021/jm500810s PMID: 25349901.
10. Tzefos M, Harris K, Brackett A. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults. The Annals of pharmacotherapy. 2012; 46(1):68-78. doi: 10.1345/aph.1Q379 PMID: 22232377.
11. Darsalia V, Hua S, Larsson M, Mallard C, Nathanson D, Nystrom T, et al. Exendin-4 reduces ischemic brain injury in normal and aged type 2 diabetic mice and promotes microglial M2 polarization. PloS one. 2014; 9(8):e103114. doi: 10.1371/journal.pone.0103114 PMID: 25101679; PubMed Central PMCID: PMC4125154.
12. Briyal S, Gulati K, Gulati A. Repeated administration of exendin-4 reduces focal cerebral ischemiainduced infarction in rats. Brain research. 2012; 1427:23-34. doi: 10.1016/j.brainres.2011.10.026 PMID: 22055454.
13. Lee CH, Yan B, Yoo KY, Choi JH, Kwon SH, Her S, et al. Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia. Journal of neuroscience research. 2011; 89(7):1103-13. doi: 10.1002/jnr.22596 PMID: 21472764.
14. Darsalia V, Mansouri S, Ortsater H, Olverling A, Nozadze N, Kappe C, et al. Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats. Clinical science. 2012; 122(10):473-83. doi: 10.1042/CS20110374 PMID: 22150224; PubMed Central PMCID: PMC3268352.
15. Sato K, Kameda M, Yasuhara T, Agari T, Baba T, Wang F, et al. Neuroprotective effects of liraglutide for stroke model of rats. International journal of molecular sciences. 2013; 14(11):21513-24. doi: 10.3390/ijms141121513 PMID: 24177570; PubMed Central PMCID: PMC3856019.
16. Tanne D. Impaired glucose metabolism and cerebrovascular diseases. Advances in cardiology. 2008; 45:107-13. doi: 10.1159/0000115190 PMID: 18230958.
17. Meloni BP, Majda BT, Knuckey NW. Establishment of neuronal in vitro models of ischemia in 96-well microtiter strip-plates that result in acute, progressive and delayed neuronal death. Neuroscience. 2001; 108(1):17-26. PMID: 11738128.
18. Zhang Z, Yan J, Taheri S, Liu KJ, Shi H. Hypoxia-inducible factor 1 contributes to N-acetylcysteine's protection in stroke. Free Radic Biol Med. 2014; 68:8-21. doi: 10.1016/j.freeradbiomed.2013.11.007 PMID: 24296245; PubMed Central PMCID: PMC3943875.
19. Dong YF, Wang LX, Huang X, Cao WJ, Lu M, Ding JH, et al. Kir6.1 knockdown aggravates cerebral ischemia/reperfusion-induced neural injury in mice. CNS neuroscience & therapeutics. 2013; 19 (8):617-24. doi: 10.1111/cns.12117 PMID: 23663330.
20. Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis RL, Bartkowski HM. Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke. 1986; 17(6):1304-8. PMID: 2433817.
21. Zhang H, Meng J, Li X, Zhou S, Qu D, Wang N, et al. Pro-GLP-1, a Pro-drug of GLP-1, is neuroprotective in cerebral ischemia. Eur J Pharm Sci. 2015; 70:82-91. doi: 10.1016/j.ejps.2015.01.010 PMID: 25640912.
22. Chen T, Wang J, Li C, Zhang W, Zhang L, An L, et al. Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition. Scientific reports. 2014; 4:5531. doi: 10.1038/srep05531 PMID: 24985053; PubMed Central PMCID: PMC4078306.
23. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. The Journal of biological chemistry. 1993; 268(26):19650-5. PMID: 8396143.
24. Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes. 1993; 42(11):1678-82. PMID: 8405712.
25. Knudsen LB, Kiel D, Teng M, Behrens C, Bhumralkar D, Kodra JT, et al. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(3):937-42. doi: 10.1073/pnas.0605701104 PMID: 17213325; PubMed Central PMCID: PMC1783418.
26. Camos S, Mallolas J. Experimental models for assaying microvascular endothelial cell pathophysiology in stroke. Molecules. 2010; 15(12):9104-34. doi: 10.3390/molecules15129104 PMID: 21150829.
27. Wu F, Echeverry R,Wu J, An J, Haile WB, Cooper DS, et al. Tissue-type plasminogen activator protects neurons from excitotoxin-induced cell death via activation of the ERK1/2-CREB-ATF3 signaling pathway. Mol Cell Neurosci. 2013; 52:9-19. doi: 10.1016/j.mcn.2012.10.001 PMID: 23063501; PubMed Central PMCID: PMC3540185.
28. Ashabi G, Khodagholi F, Khalaj L, Goudarzvand M, Nasiri M. Activation of AMP-activated protein kinase by metformin protects against global cerebral ischemia in male rats: interference of AMPK/PGC-1alpha pathway. Metab Brain Dis. 2014; 29(1):47-58. doi: 10.1007/s11011-013-9475-2 PMID: 24435937.
29. Nakka VP, Gusain A, Raghubir R. Endoplasmic reticulum stress plays critical role in brain damage after cerebral ischemia/reperfusion in rats. Neurotox Res. 2010; 17(2):189-202. doi: 10.1007/s12640-009-9110-5 PMID: 19763736.
30. MacManus JP, Buchan AM. Apoptosis after experimental stroke: fact or fashion? J Neurotrauma. 2000; 17(10):899-914. PMID: 11063056.
31. Sairanen T, Karjalainen-Lindsberg ML, Paetau A, Ijas P, Lindsberg PJ. Apoptosis dominant in the periinfarct area of human ischaemic stroke - a possible target of antiapoptotic treatments. Brain. 2006; 129 (Pt 1):189-99. doi: 10.1093/brain/awh645 PMID: 16272167.
32. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007; 132(6):2131-57. doi: 10.1053/j.gastro.2007.03.054 PMID: 17498508.
33. Perry T, Greig NH. The glucagon-like peptides: a double-edged therapeutic sword? Trends Pharmacol Sci. 2003; 24(7):377-83. doi: 10.1016/S0165-6147(03)00160-3 PMID: 12871671.
34. Hoare SR. Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. Drug Discov Today. 2005; 10(6):417-27. PMID: 15808821.
35. Pyke C, Heller RS, Kirk RK, Orskov C, Reedtz-Runge S, Kaastrup P, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014; 155(4):1280-90. doi: 10.1210/en.2013-1934 PMID: 24467746.
36. Panjwani N, Mulvihill EE, Longuet C, Yusta B, Campbell JE, Brown TJ, et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology. 2013; 154(1):127-39. doi: 10.1210/en.2012-1937 PMID: 23183176.
37. Pyke C, Knudsen LB. The glucagon-like peptide-1 receptor - or not? Endocrinology. 2013; 154(1):4-8. doi: 10.1210/en.2012-2124 PMID: 23267050.
38. Wu Z, Liu S, Nair I, Omori K, Scott S, Todorov I, et al. (64)Cu labeled sarcophagine exendin-4 for micro-PET imaging of glucagon like peptide-1 receptor expression. Theranostics. 2014; 4(8):770-7. doi: 10.7150/thno.7759 PMID: 24955138; PubMed Central PMCID: PMC4063975.
39. Green CJ, Henriksen TI, Pedersen BK, Solomon TP. Glucagon like peptide-1-induced glucose metabolism in differentiated human muscle satellite cells is attenuated by hyperglycemia. PloS one. 2012; 7(8): e44284. doi: 10.1371/journal.pone.0044284 PMID: 22937169; PubMed Central PMCID: PMC3429413.
40. Ding L, Zhang J. Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. Acta pharmacologica Sinica. 2012; 33(1):75-81. doi: 10.1038/aps.2011.149 PMID: 22120969; PubMed Central PMCID: PMC4010269.
41. Lin F, Wang R. Molecular modeling of the three-dimensional structure of GLP-1R and its interactions with several agonists. Journal of molecular modeling. 2009; 15(1):53-65. doi: 10.1007/s00894-008-0372-2 PMID: 18941807.
42. Lopez de Maturana R, Willshaw A, Kuntzsch A, Rudolph R, Donnelly D. The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1. The Journal of biological chemistry. 2003; 278(12):10195-200. doi: 10.1074/jbc.M212147200 PMID: 12524435.
43. Turner RC, Dodson SC, Rosen CL, Huber JD. The science of cerebral ischemia and the quest for neuroprotection: navigating past failure to future success. Journal of neurosurgery. 2013; 118(5):1072-85. doi: 10.3171/2012.11.JNS12408 PMID: 23331000.
44. Sanderson TH, Kumar R, Murariu-Dobrin AC, Page AB, Krause GS, Sullivan JM. Insulin activates the PI3K-Akt survival pathway in vulnerable neurons following global brain ischemia. Neurological research. 2009; 31(9):947-58. doi: 10.1179/174313209X382449 PMID: 19203442.